tetano
Editor, Senior Moderator
Life Sci
. 2024 Jul 29:122938.
doi: 10.1016/j.lfs.2024.122938. Online ahead of print. Understanding the mechanisms and treatments of long COVID to address future public health risks
Bohao Li[SUP] 1 [/SUP], Junlu Bai[SUP] 1 [/SUP], Yan Xiong[SUP] 1 [/SUP], Dong Guo[SUP] 1 [/SUP], Beibei Fu[SUP] 1 [/SUP], Guohong Deng[SUP] 2 [/SUP], Haibo Wu[SUP] 3 [/SUP]
Affiliations
The 2019 coronavirus disease (COVID-19), triggered by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), has seen numerous individuals undergo and recover from it, drawing extensive attention to their health conditions. Extensive studies indicate that even after surpassing the acute phase of infection, patients continue to experience persistent symptoms such as fatigue, pain, depression, weakening, and anosmia. COVID-19 appears not to have concluded but rather to persist long-term in certain individuals, termed as "long COVID." This represents a heterogeneous ailment involving multiple organ systems, with a perceived complex and still elusive pathogenesis. Among patients with long COVID, observations reveal immune dysregulation, coagulation impairments, and microbial dysbiosis, considered potential mechanisms explaining sustained adverse outcomes post COVID-19. Based on the multifactorial nature, varied symptoms, and heterogeneity of long COVID, we have summarized several categories of current therapeutic approaches. Furthermore, the symptoms of long COVID resemble those of other viral illnesses, suggesting that existing knowledge may offer novel insights into long-term COVID implications. Here, we provide an overview of existing literature associated with long COVID and summarize potential mechanisms, treatment modalities, and other analogous conditions. Lastly, we underscore the inadequacies in long COVID treatment approaches and emphasize the significance of conducting further research and clinical trials.
Keywords: COVID-19; Coronavirus; Long COVID; SARS-CoV-2; Therapies.
. 2024 Jul 29:122938.
doi: 10.1016/j.lfs.2024.122938. Online ahead of print. Understanding the mechanisms and treatments of long COVID to address future public health risks
Bohao Li[SUP] 1 [/SUP], Junlu Bai[SUP] 1 [/SUP], Yan Xiong[SUP] 1 [/SUP], Dong Guo[SUP] 1 [/SUP], Beibei Fu[SUP] 1 [/SUP], Guohong Deng[SUP] 2 [/SUP], Haibo Wu[SUP] 3 [/SUP]
Affiliations
- PMID: 39084516
- DOI: 10.1016/j.lfs.2024.122938
The 2019 coronavirus disease (COVID-19), triggered by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), has seen numerous individuals undergo and recover from it, drawing extensive attention to their health conditions. Extensive studies indicate that even after surpassing the acute phase of infection, patients continue to experience persistent symptoms such as fatigue, pain, depression, weakening, and anosmia. COVID-19 appears not to have concluded but rather to persist long-term in certain individuals, termed as "long COVID." This represents a heterogeneous ailment involving multiple organ systems, with a perceived complex and still elusive pathogenesis. Among patients with long COVID, observations reveal immune dysregulation, coagulation impairments, and microbial dysbiosis, considered potential mechanisms explaining sustained adverse outcomes post COVID-19. Based on the multifactorial nature, varied symptoms, and heterogeneity of long COVID, we have summarized several categories of current therapeutic approaches. Furthermore, the symptoms of long COVID resemble those of other viral illnesses, suggesting that existing knowledge may offer novel insights into long-term COVID implications. Here, we provide an overview of existing literature associated with long COVID and summarize potential mechanisms, treatment modalities, and other analogous conditions. Lastly, we underscore the inadequacies in long COVID treatment approaches and emphasize the significance of conducting further research and clinical trials.
Keywords: COVID-19; Coronavirus; Long COVID; SARS-CoV-2; Therapies.